Preparation and property analysis of a hepatocyte targeting pH-sensitive liposome

World Journal of Gastroenterology

Volumn 10, Issue 2, 2004, Pages 244-249

  Wen, Si Yuan ^a   Wang, Xiao Hong ^a   Lin, Li ^a   Guan, Wei ^a   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ASIALOGLYCOPROTEIN RECEPTOR; GALACTOSE; LIPID; LIPOSOME; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID;

ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ERYTHROCYTE; GENE EXPRESSION; GENETIC TRANSFECTION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LIVER CELL; LIVER TUMOR; METABOLISM; METHODOLOGY; PH; PLASMID; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

EID: 1042304308     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i2.244     Document Type: Article

References (30)

1. Heintges T, Encke J, Zu Putlitz J, Wands JR. Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J Med Virol 2001; 65: 671-680
2. Robaczewska M, Guerret S, Remy JS, Chemin I, Offensperger WB, Chevallier M, Behr JP, Podhajska AJ, Blum HE, Trepo C, Cova L. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxy nucleotides to the liver. Gene Ther 2001; 8: 874-881
3. Alt M, Eisenhardt S, Serwe M, Renz R, Engels JW, Caselmann WH. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation. Eur J Clin Inves 1999; 29: 868-876
4. Alt M, Renz R, Hofschneider PH, Caselmann WH. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation. Arch Virol 1997; 142: 589-599
5. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatits C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 1995; 22: 707-717
6. Liu Y, Chen Z, He N. Inhibition of hepatitis C virus by antisense oligodeoxynucleotide in vitro. Zhonghua Yixue Zazhi 1997; 77: 567-570
7. Zabner J. Cationic lipids used in gene transfer. Adv Drug Deliv Rev 1997; 27: 17-28
8. Kim JK, Choi SH, Kim CO, Park JS, Ahn WS, Kim CK. Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: Effects on serum stability and transfection efficiency. J Pharm Pharmacol 2003; 55: 453-460
9. Abra RM, Bankert RB, Chen F, Egilmez NK, Huang K, Saville R, Slater JL, Sugano M, Yokota SJ. The next generation of liposome delivery systems: Recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res 2002; 12: 1-3
10. Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999; 40: 103-127
11. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Egan JJ, Sorgi FL, Huang L, Cuthbert AW, Evans MJ, Colledge WH, Higgins CF, Webb AK, Gill DR. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000; 7: 1156-1165
12. Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7: 2285-2291
13. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial. J Clin Oncol 2001; 19: 3422-3433
14. Hui KM, Ang PT, Huang L, Tay SK. Phase I suty of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther 1997; 4: 783-790
15. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, Thomson A, MacVinish LJ, Ratcliff R, Bilton D, Lane DJ, Littlewood JM, Webb AK, Middleton PG, Colledge WH, Cuthbert AW, Evans MJ, Higgins CF, Hyde SC. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4: 199-209
16. Gao S, Chen J, Xu X, Ding Z, Yang YH, Hua Z, Zhang J. Galactosylated low molecular weight chitosan as DNA carrier for hepatocyte-targeting. Int J Pharm 2003; 255: 57-68
17. Kunath K, Von Harpe A, Fischer D, Kissel T. Galatose-PEI-DNA complexes for targeted gene delivery: Degree of substitution affects complex size and transfection efficiency. J Control Release 2003; 88: 159-172
18. Yuan L, He S, Guan C, Pang Q. The preparation and study on hepatic targeting tendency of galactosyl-anti-CD3-McAb in mice. Huaxi Yike Daxue Xuebao 2001; 32: 424-426
19. Kawakami S, Yamashita F, Nishikawa M, Takakura Y, Hashida M. Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes. Biochem Biophys Res Commun 1998; 252: 78-83
20. Hara T, Kuwasawa H, Aramaki Y, Takada S, Koike K, Ishidate K, Kato H, Tsuchiya S. Effects of fusogenic and DNA-binding amphiphilic compounds on the receptor-mediated gene transfer into hepatic cells by asialofetuin-labeled liposomes. Biochim Biophys Acta 1996; 1278: 51-58
21. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280-285
22. Wang XH, Wang SQ, Li MD, Zhu BZ. Establishment of a HCV 5′ NCR transgenic cell model. Bingdu Xuebao 1998; 14: 296-301
23. Smits E, Ernberts FN, Kellogg RM. Reliable method for the synthesis of aryl b-D-glycopyranosides, using boron trifluoride-diethyl ether as catalysts. J Chem Soc Perkin Trans 1996: 2873-2877
24. Lubineu A, Queneau Y. Aqueous cycloadditions using gluco-organic substrates 1. Stereo- chemical course of the reaction. J Org Chem 1987; 52: 1001-1009
25. Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem 1994; 269: 14205-14210
26. Chen J, Simon RP, Nagayama T, Zhu R, Loeffert JE, Watkins SC, Graham SH. Suppression of endogenous bcl-2 expression by antisense treatment exacerbates ischemic neuronal death. J Cereb Blood Flow Metab 2000; 20: 1033-1039
27. Venugopalan P, Jain S, Sankar S, Singh P, Rawat A, Vyas SP. pH-sensitive liposomes: Mechanism of triggered release to drug and gene delivery prospects. Pharmazie 2002; 57: 659-671
28. Simoes S, Slepushkin V, Duzgunes N, Pedroso De Lima MC. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta 2001; 1515: 23-37
29. Simoes S, Slepushkin V, Pires P, Gaspar R, De Lima MP, Duzgunes N. Mechanisms of gene transfer mediated by lipoplexes assocaiated with targeting ligand or pH-sensitive peptides. Gene Ther 1999; 6: 1798-1807
30. Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta 1995; 1235: 296-304